Eldon C. Mayer III - Jan 7, 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role: Ex VP & Chief Commerc. Officer
Signature: /s/ Sriram Ryali, Attorney-in-Fact
Stock symbol: EIGR
Transactions as of: Jan 7, 2022
Transactions value $: -$7,722
Form type: 4
Date filed: 1/11/2022, 07:59 PM
Previous filing: Jul 30, 2021
Next filing: Mar 11, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EIGR	Common Stock	Sale	-$7.72K	-1.56K	-3.27%	$4.95	46.1K	Jan 7, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on January 31, 2020 for 7,500 shares.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.95 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on January 31, 2020 for 7,500 shares.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.95 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.